---

Pharmaceuticals

• Zydus Cadila's U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. has received

final approval from the USFDA to market Apremilast Tablets in the strengths

of 10 mg, 20 mg, 30 mg (US RLD: Otezla® Tablets). Zydus' Apremilast Tablets

are indicated for the treatment of adult patients with moderate to severe

plaque psoriasis who are candidates for phototherapy or systemic therapy.

The drug will be manufactured at the group's formulation manufacturing

facility at the SEZ, Ahmedabad.